Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression

被引:130
作者
Huang, Yulun [1 ]
Zhou, Youxin [1 ]
Fan, Yisun [1 ]
Zhou, Dai [1 ]
机构
[1] Suzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Peoples R China
关键词
celastrol; antiangiogenesis; VEGFR; glioma; VEGF;
D O I
10.1016/j.canlet.2008.01.043
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Celastrol, a compound purified from Tripterygium wilfordii whose preparations have been used for clinical treatment for rheumatoid arthritis, has been demonstrated to have antiangiogenic activity, and be inhibitory against mice tumor growth by a few recent studies. However, whether its antiangiogenic activity plays a role in the celastrol-mediated suppression of tumor growth and the molecular basis of anti-tumor activity are poorly understood. In this study, we found that celastrol inhibited the growth of human glioma xenografts in mice, which concurred with the suppression of angiogenesis. Interestingly, while celastrol had no effect on either the expression of VEGF or its mRNA levels, celastrol treatment lowered the expression levels of its receptors (VEGFR-1 and VEGFR-2) and their mRNA levels. These findings suggest that celastrol have potential to be used as an antiangiogenesis drug through its role in suppressing VEGF receptors expression that might consequently reduce the signal transduction between VEGF and VEGFR. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 25 条
  • [1] A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients
    Chang, JT
    Chen, IH
    Liao, CT
    Wang, HM
    Hsu, YM
    Hung, KF
    Lin, CJ
    Hsieh, LL
    Cheng, AJ
    [J]. CLINICAL BIOCHEMISTRY, 2002, 35 (08) : 591 - 596
  • [2] Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and-2 in human neuroblastoma
    Fakhari, M
    Pullirsch, D
    Abraham, D
    Paya, K
    Hofbauer, R
    Holzfeind, P
    Hofmann, M
    Aharinejad, S
    [J]. CANCER, 2002, 94 (01) : 258 - 263
  • [3] THE IMPLICATIONS OF ANGIOGENESIS FOR THE BIOLOGY AND THERAPY OF CANCER METASTASIS
    FIDLER, IJ
    ELLIS, LM
    [J]. CELL, 1994, 79 (02) : 185 - 188
  • [4] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE
    FOLKMAN, J
    [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31
  • [5] FRIEDRICHS K, 1993, CANCER, V72, P3641, DOI 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO
  • [6] 2-8
  • [7] Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis
    Grosios, K
    Wood, J
    Esser, R
    Raychaudhuri, A
    Dawson, J
    [J]. INFLAMMATION RESEARCH, 2004, 53 (04) : 133 - 142
  • [8] Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine
    He, W
    Huang, FC
    Gavai, A
    Chan, WK
    Amato, G
    Yu, KT
    Zilberstein, A
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (24) : 3659 - 3664
  • [9] Novel cytokine release inhibitors. Part I: Triterpenes
    Huang, FC
    Chan, WK
    Moriarty, KJ
    Zhang, DC
    Chang, MN
    He, W
    Yu, KT
    Zilberstein, A
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (14) : 1883 - 1886
  • [10] Huang Yu-lun, 2003, Zhonghua Zhongliu Zazhi, V25, P429